"The US Food and Drug Administration (USFDA) has approved the
abbreviated new drug application filed by Granules Pharmaceuticals,
Inc, a wholly owned foreign subsidiary of Granules India Ltd, for
Trospium Chloride extended-release capsules, 60 mg," the company said
in a regulatory filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/granules-india-gets-usfda-nod-for-overactive-bladder-treatment-capsule/articleshow/75344959.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment